sur Morphogenesis Inc.
TuHURA Biosciences to Showcase Clinical Trial Results at ASCO 2024
TuHURA Biosciences, Inc., a company progressing to Phase 3 and specializing in immune-oncology, announced its upcoming presentation at the ASCO Annual Meeting in Chicago from May 31 to June 4, 2024. The poster presentation will focus on the Phase 1b trial results of their IFx-2.0 vaccine, targeting resistant Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC). Dr. Andrew Brohl from the Moffitt Cancer Center will present on June 1.
In a significant development, TuHURA also disclosed a definitive all-stock merger with Kintara Therapeutics. This agreement includes a substantial $31 million financing to help advance a diversified late-stage oncology pipeline. The merged entity will continue under the name TuHURA Biosciences and will be listed on the Nasdaq Capital Market under the ticker "HURA". Completion of this merger is subject to customary closing conditions and is anticipated in the third quarter of 2024.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Morphogenesis Inc.